Free tool
FAERS Monitor: Xeloda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020896 or its brand name (Xeloda, Capecitabine). Reports on generic versions are filed under their own applications.
Reports
91,426
Serious
75,506
83% of reports
Hospitalization
29,053
Death reported
18,299
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea13,713
- death8,788
- nausea8,520
- palmar-plantar erythrodysaesthesia syndrome6,691
- fatigue6,544
- vomiting6,327
- disease progression6,093
- malignant neoplasm progression4,032
- off label use3,895
- asthenia3,441
- decreased appetite3,305
- neutropenia3,161
- neuropathy peripheral2,944
- dehydration2,742
- dyspnoea2,690
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 642 |
| 2005 | 823 |
| 2006 | 959 |
| 2007 | 1,734 |
| 2008 | 2,153 |
| 2009 | 2,779 |
| 2010 | 2,889 |
| 2011 | 2,581 |
| 2012 | 5,959 |
| 2013 | 4,267 |
| 2014 | 3,115 |
| 2015 | 2,958 |
| 2016 | 2,929 |
| 2017 | 6,962 |
| 2018 | 4,771 |
| 2019 | 5,424 |
| 2020 | 6,546 |
| 2021 | 7,740 |
| 2022 | 7,175 |
| 2023 | 5,940 |
| 2024 | 5,255 |
| 2025 | 4,705 |
| 2026 | 3,120 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,962,733 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palmar-plantar erythrodysaesthesia syndromeSignal | 6,691 | 92.2 | 89.7 | 430,799 |
| disease progressionSignal | 6,093 | 12.4 | 12.1 | 61,105 |
| malignant neoplasm progressionSignal | 4,032 | 9.4 | 9.1 | 29,161 |
| neuropathy peripheralSignal | 2,944 | 7.3 | 7.1 | 15,618 |
| neutropeniaSignal | 3,161 | 5.5 | 5.3 | 11,292 |
| diarrhoeaSignal | 13,713 | 5.0 | 4.9 | 43,928 |
| dehydrationSignal | 2,742 | 4.8 | 4.6 | 8,147 |
| decreased appetiteSignal | 3,305 | 3.3 | 3.2 | 5,298 |
| vomitingSignal | 6,327 | 3.1 | 3.1 | 9,220 |
| nauseaSignal | 8,520 | 2.5 | 2.4 | 7,826 |
| deathSignal | 8,788 | 2.4 | 2.3 | 7,111 |
| astheniaSignal | 3,441 | 2.1 | 2.0 | 2,041 |
| fatigue | 6,544 | 1.9 | 1.9 | 3,076 |
| dyspnoea | 2,690 | 1.1 | 1.1 | 22 |
| off label use | 3,895 | 1.0 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.